Helix BioPharma Corp. (HBP)

Toronto
0.550
-0.030(-5.17%)
  • Volume:
    2,980
  • Bid/Ask:
    0.520/0.580
  • Day's Range:
    0.550 - 0.580
  • Type:Equity
  • Market:Canada
  • ISIN:CA4229101098
  • CUSIP:422910109

HBP Overview

Prev. Close
0.58
Day's Range
0.55-0.58
Revenue
-
Open
0.58
52 wk Range
0.25-1.16
EPS
-0.06
Volume
2,980
Market Cap
81.86M
Dividend (Yield)
N/A
(N/A)
Average Volume (3m)
12,318
P/E Ratio
-
Beta
-0.09
1-Year Change
48.65%
Shares Outstanding
141,133,017
Next Earnings Date
Nov. 04, 2021
What is your sentiment on Helix BioPharma Corp.?
or
Market is currently closed. Voting is open during market hours.

Helix BioPharma Corp. News

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyBuySellStrong Sell
SummaryNeutralNeutralNeutralStrong SellStrong Sell

Helix BioPharma Corp. Company Profile

Helix BioPharma Corp. Company Profile

Sector
Services
Employees
10
Market
Canada

Helix BioPharma Corp. is an immuno-oncology company, which specializes in the field of cancer therapy. The Company is developing products for the prevention and treatment of cancer based on its technologies. The Company's product development initiatives are focused primarily on technologies that modulate the tumor microenvironment. The Company's technology platform, DOS47 yielded approximately two drug product candidates, L-DOS47 and vDOS47. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. L-DOS47 is under clinical study for the treatment of non-small cell lung cancer (NSCLC). L-DOS47 has completed preclinical testing and manufacturing development, following which, regulatory approvals are obtained in Poland and the United States to conduct Phase I/II and Phase I clinical studies. V-DOS47 is an antibody DOS47 conjugate that targets the vascular endothelial growth factor 2 receptor (VEGFR2).

Read More
  • it got approved by FDA From USA for new drugs
    0
    • Looks like some insiders know something we don't
      0
      Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
      Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.